This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Eosinophilic Esophagitis
  • /
  • AGA Institute and the Joint Task Force on Allergy-...
Guideline

AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis

Read time: 1 mins
Last updated:30th Apr 2020
Availability: Free full text
Status: Live
AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis


Eosinophilic esophagitis (EoE) was first characterized as a distinct clinical entity by Attwood and Straumann in the early 1990s. While understood to be a food antigen-driven Th2 inflammatory condition, there is a large body of evidence that EoE patients have aeroallergen sensitization and concurrent atopic diseases, including asthma, allergic rhinitis, and eczema. There is a close interaction between these organ-specific diseases and potential for common triggering antigens in EoE and other atopic conditions. A dramatic rise in the recognition of EoE in the United States, first in pediatrics and subsequently in adults, was paralleled by an increase in publications on EoE. The past 25 years have witnessed the emergence of the field from small case series and observational studies to larger, international, multicenter, randomized controlled trials (RCTs) of both medical and dietary therapies. This guideline provides evidence-based recommendations focusing on the clinical management of EoE for both pediatric and adult allergists and gastroenterologists.


Read full Guideline